12-14% of GLP-1 Patients may be Slow or Non-Responders:

Table of Contents

GLP-1 weight-loss medications have changed the treatment of obesity. Drugs such as semaglutide and tirzepatide can produce major weight loss for many patients. In the STEP 1 semaglutide trial, 86.4% of patients taking semaglutide 2.4 mg achieved at least 5% body weight loss(the threshold for a response) indicating that most patients responded well. HOWEVER THERE ARE MANY PATIENTS WHO RESPOND SLOWLY OR NOT AT ALL! HOW TO IDENTIFY THEM!

With 86.4% doing well, what about the other 13.6% who did not reach the 5% threshold, even in a carefully monitored clinical trial This group is important -sSome patients adhere to the medication regimen and dose escalation but still lose weight, slowly, delayed, or not at all little.. The question is how to identify them and why it happens.

A practical office definition of a GLP-1 non-responder is:

A patient who loses less than 5% of starting body weight after an adequate dose, adequate duration, good adherence, correct injection technique, and review of other causes of poor weight loss. Table 1 presents the types of responders:

Table 1: Types of GLP-1 Responders

A colorful table titled "Types of Responses to GLP-1 Medications" outlines four patterns of patient responses. Each category details weight loss indicators and implications. The chart visually emphasizes how to identify GLP-1 non-responders, with a note that they represent about 12-14% of individuals.

Why Some People Do Not(or Slowly) Respond to GLP-1 Weight Loss Drugs

Most people lose weight when taking GLP-1 medications, but a small number experience: SLOW, DELAYED, LITTLE OR NO WEIGHT CHANGE. This usually isn’t because they are “doing everything wrong.” Often, it comes down to biology. Obesity isn’t just one disease. It’s a group of conditions that involve factors such as appetite signals, reward pathways, insulin resistance, gut hormones, genetics, medications, sleep, stress, muscle mass, and the body’s adaptation to change. There may be biological, genetic, and other factors affecting the efficacy of these medications. Here are some factors to consider:

• Biological variation in GLP-1 receptors: Some people naturally have fewer or less sensitive GLP-1 receptors, meaning the medication’s appetite-lowering and gastric-slowing effects may not work as strongly— similar to how people react more or less to blood pressure or cholesterol medications.

• Genetic differences affecting appetite hormones: Variants in genes linked to appetite regulation can reduce how strongly GLP-1’s reduce hunger.

• Coexisting medical conditions such as:
Cushing syndrome,
Polycystic ovary syndrome
Steatotic liver disease
Heavy alcohol use.

Concurrent Medications:
Medications, such as steroids, Beta blockers, Gabapentin, antipsychotics, and some diabetes drugs, can biologically interfere with the weight loss achieved through GLP-1 medications.

If weight loss remains less than 5% after a proper trial, the patient should be considered a poor responder and offered an alternative approach rather than simply increasing the dose.

How to Turn Non-Responders into Weight Loss Responders

Exercise and Special Diets to Increase Weight Loss

These are important for overall health, muscle maintenance, improved insulin sensitivity, and long-term weight maintenance. However, they rarely turn a true GLP-1 non-responder into someone who loses a significant amount of weight.
Eating more protein, cutting back on carbs, and doing resistance training can help your body composition, but these changes should not be promised as a fix for when the drug does not work

Switching to another GLP-1 Medications to Increase Weight loss:

For people who truly do not respond, switching from one GLP-1 drug to another usually does not help unless you are moving from a weaker drug to a stronger one like semaglutide to tirzepatide, or from an oral to injectable drug. The new oral small molecule GLP-1, Foundayo may increase the weight loss. Sometimes if the new drug is easier to tolerate and its easier to stick with the treatment..

Taking Breaks from the Medication:

This usually does not help people who are not responding. For those who do respond, stopping the drug often leads to hunger and weight gain . This shows that these medications work best when used long-term, not just for short periods. Graph #1 shows studies in which participants stopped taking semaglutide, those who continued to take it maintained

Graph #1

A bar graph titled 'Tirzepatide Weight-Loss Non-Responders by Study and Dose Group' displays percentage data from various studies. Each colorful bar represents the non-responder rates across studies, emphasizing data relevant for identifying GLP-1 Non-responders.

Evaluating an Individual for Non-responsiveness to GLP-1 drugs

Step 1: Confirm an Adequate Trial: Do not classify a patient as a GLP-1 non-responder after only a few initial doses:

Semaglutide treated patients such as Wegovy or Ozempic. The patient should generally have at least 12–16 weeks of treatment, and preferably longer if dose escalation has been slow.

Tirzepatide treated patients such as Zepbound or Mounjaro. The patient should generally have at least 12–16 weeks of treatment, preferably after reaching at least a moderate dose if tolerated. A stronger diagnosis of non-response is made after 24 weeks or more of adequate treatment, especially if the patient has remained below 5% total body-weight loss.

Classify the Patient’s Response:

Excellent responder: 10% or more body-weight loss by 6–12 months.

Partial responder: 5% to 9.9% body-weight loss.

Poor responder: 3% to 4.9% body-weight loss after an adequate treatment trial.

Confirmed non-responder: Less than 5% body-weight loss after 24 weeks or longer,

How Common Are GLP-1 Non-Responders?

The best practical estimate is:

About 15% to 20% of real-world GLP-1 users may be poor(or slow) responders or non-responders.This estimate is approximate and depends on factors such as drug type, dose, diagnosis, treatment duration, diabetes status, side effects, cost, adherence, and treatment continuity.

In clinical trials, the non-response percentage is usually lower because patients are closely monitored, medications are supplied and follow-up is structured.

In real-world practice, the percentage is often higher due to cost barriers, medication shortages, missed doses, side effects, inconsistent dose escalation, compounded product variability, and less intensive lifestyle support.

Semaglutide Trial Evidence

In STEP 1, semaglutide 2.4 mg weekly produced large average weight loss in adults with overweight or obesity. However, 86.4% of patients achieved at least 5% body-weight loss, meaning about 13.6% did not reach that threshold.This provides clear evidence that a minority of patients do not achieve clinically meaningful weight loss, even in well-conducted clinical trials.

Tirzepatide Trial Evidence

Tirzepatide typically results in greater average weight loss than semaglutide, but it is not effective for all patients.

In SURMOUNT-1, Lilly reported that 89% of patients taking tirzepatide 5 mg and 96% of patients taking 10 mg or 15 mg achieved at least 5% body-weight loss. This means that approximately 11% at the 5 mg dose and 4% at the 10–15 mg doses did not reach the 5% threshold.

The NEJM SURMOUNT-1 publication reported substantial and sustained weight reductions with once-weekly tirzepatide in adults with obesity, with average weight reductions of 19.5% and 20.9% at the 10 mg and 15 mg doses.

Real-World Evidence of Effectiveness.

Real-world studies demonstrate greater variability in outcomes compared to clinical trials.One 2025 real-world study reported an average weight loss of 12.2%, but 17.8% of participants were classified as non-responders. This supports the practical estimate that 15% to 20% of patients in routine practice may have poor or minimal weight-loss response, particularly when accounting for adherence issues, medication access, lower doses, and side effects.

How Many People are Poor or Non-Responders?

In November 2025 that 12% of U.S. adults were currently taking a GLP-1 drug, and 18% had taken one at some point.Using an approximate U.S. adult population of about 260 million, that suggests:

U.S. adults currently taking a GLP-1	31 million
U.S. adults who have ever taken a GLP-1	47 million
Current users who may be poor/non-responders at 15%	4.7 million
Current users who may be poor/non-responders at 20%	6.2 million
Ever-treated users who may be poor/non-responders at 15%	7.0 million
Ever-treated users who may be poor/non-responders at 20%	9.4 million

If about 31 million U.S. adults are currently using GLP-1 drugs, and 15% to 20% have poor or minimal weight-loss response, roughly 5 to 6 million current users may be poor responders or non-responders. Among all adults who have ever tried a GLP-1 drug, the number could be closer to 7 to 9 million.

These figures are estimates and include individuals using GLP-1 drugs for diabetes, weight loss, cardiovascular risk reduction, or other chronic conditions.

How slow or non-responders can be assisted in their weight loss?

GLP-1 non-response is a recognized phenomenon. While most patients lose weight with semaglutide or tirzepatide, a consistent minority do not achieve the standard 5% body-weight loss threshold. In clinical trials, non-responder rates range from approximately 4% to 14%, depending on the drug and dose. In real-world practice, approximately 15% to 20% of patients have a poor or minimal response.

These patients deserve a careful medical evaluation, not blame. A structured office protocol can separate true biologic non-response from underdosing, missed doses, side effects, medication access problems, diabetes-related reduced response, weight-promoting drugs, and other medical causes.